Malaria Vaccine

# Malaria Vaccines Offer Hope Amid Climate and Funding Challenges

Recent developments in malaria prevention and treatment are bringing both promise and concern as global health experts grapple with rising cases and funding pressures across Africa.

According to the World Health Organization, malaria vaccines are now being introduced in 25 African countries, marking a significant milestone in disease prevention efforts. The WHO reports that vaccines have saved more than 50 million lives in Africa over the past five decades, with 2024 alone seeing nearly 2 million lives saved through vaccination programs. This progress represents a critical advancement in addressing a disease...

In the past two days, global health discussions have spotlighted malaria prevention amid ongoing challenges in vaccine distribution and funding. The World Health Organization reports that vaccination programs across Africa have saved over 50 million lives in the past five decades, with malaria vaccines playing a key role in high-burden regions like South Africa and Zimbabwe, though U.S. aid cuts threaten future progress, according to The Independent.

Uganda stands out with fresh momentum in local production. The Office of the Prime Minister announced that the GAVI Vaccine Alliance will support Uganda's manufacture of malaria vaccines starting this month...

A Johns Hopkins University malaria expert warned on April 12 that rising global cases and deaths underscore the limits of existing vaccines, with World Health Organization data showing 282 million infections and 610,000 fatalities in 2024, up from prior years despite WHO approvals of RTS,S (Mosquirix) in 2021 and R21 in 2023 now used in 24 countries. Jane M. Carlton emphasized that these vaccines reduce child cases by over 50 percent in the first year after three doses, but protection wanes without a fourth, and delivery challenges persist in rural areas, madhyamamonline.com reported. She stressed combining them with bed nets, drugs, and mosquito control, amid growing...

A Johns Hopkins University expert warns that malaria cases are rising globally despite the rollout of two WHO-approved vaccines, RTS,S (Mosquirix) and R21, now deployed in 24 countries since their approvals in 2021 and 2023, according to a Dailyhunt report from Madhyamam English. The vaccines reduce severe cases in children by over 50 percent in the first year after three doses, with a fourth recommended to extend waning protection, yet transmission persists amid challenges like supply and access.

Rotary International highlights optimism from these breakthroughs, noting modeling by the WHO that scaled distribution could save half a million children's lives by 2035...

# Malaria Vaccines Show Promise Despite Growing Challenges

The global fight against malaria is entering a critical phase with newly approved vaccines offering hope, yet experts warn that vaccination alone cannot solve the crisis as resistance to treatments and insecticides continues to spread.

Two breakthrough malaria vaccines, Mosquirix and R21, have demonstrated significant impact since their WHO approval in 2021 and 2023. According to Rotary International, these vaccines have reduced malaria cases in children by more than 50 percent during the first year after the initial series of three doses, with a fourth booster dose recommended after one year to...

Malaria vaccine rollout across Africa is accelerating despite funding cuts and supply strains, with Gavi reporting on January 28, 2026, that 25 countries have integrated WHO-endorsed RTS,S (Mosquirix) and R21 vaccines into routine immunization programs. These shots, which reduce child cases by over 50 percent in the first year after dosing, are building on successes like Kenya's Malaria Vaccine Implementation Programme, where RTS,S—developed over 35 years by GlaxoSmithKline with WHO, Gavi, and PATH support—has lowered deaths and hospitalizations in young children since 2019, according to Tropical Health Matters.

Recent momentum includes Nigeria's Bauchi State launching a major March drive targeting poli...

Recent developments in malaria control highlight the expanding rollout of approved vaccines amid ongoing challenges like funding cuts and supply shortages. As of January 28, 2026, Gavi reports that 25 African countries have integrated malaria vaccines into routine immunization programs with its support, building on the WHO-endorsed RTS,S (Mosquirix) and R21 shots, which reduce child cases by over 50 percent in the first year after dosing.

In Nigeria, Bauchi State Government flagged off a major March immunization drive through its Primary Healthcare Development Board, targeting polio and malaria vaccines for two million children under five, signaling accelerated local deployment. Tropical Health...

Recent developments in malaria control highlight ongoing challenges and progress with vaccines like RTS,S and R21, amid supply shortages and new research insights. Tropical Health Matters reports that since 2019, Kenya's pilot Malaria Vaccine Implementation Programme has significantly reduced death rates and hospitalizations in children under 2, thanks to the RTS,S vaccine developed by GlaxoSmithKline over 35 years, with support from WHO, GAVI, and PATH. Similar gains have been seen in Ghana and Malawi through WHO-led rollouts integrated with routine immunizations and malaria interventions.

Demand for these vaccines far exceeds supply, according to UNICEF, raising concerns over production, supply...

In the past two days, no major breaking news on malaria or its vaccines has emerged from global health outlets, but ongoing procurement efforts and public health discussions underscore persistent challenges in malaria control. South Africa's National Department of Health published its latest tenders list as of March 30, 2026, including a recent request for quotations on basic life support equipment closing that day, though longer-term bids highlight malaria priorities, such as the prior NDOH 02-2025/2026 tender for supplying malaria rapid diagnostic tests (RDTs) over three years, awarded earlier in 2025, according to the department's procurement portal.

This reflects sustained efforts...

A new U.S. global health policy is emerging as a potential game-changer in the fight against malaria, particularly in sub-Saharan Africa, where cases continue to rise. OSV News reports that the Trump administration's America First Global Health Strategy, unveiled in September, aims to shift toward country-led malaria control by encouraging public and private funders in endemic nations to take responsibility for their efforts. This approach seeks to meet 2030 goals of slashing global malaria mortality and incidence by 90% from 2015 levels and eliminating the disease in 35 countries. An interfaith coalition's February report, cited by OSV News, warns of stalled progress amid...

A new study published on MalariaWorld on March 25 reveals suboptimal uptake of the R21/Matrix-M malaria vaccine in Sudan, where it was introduced in 2024 through routine immunization in two states. MalariaWorld reports that the study identifies key barriers behind this low adoption, highlighting challenges in vaccine rollout amid ongoing health system strains.

Shifting focus to Togo, Malaria Consortium's StRIVE project is actively strengthening routine immunization to boost uptake of the R21 malaria vaccine. The initiative supports effective vaccine engagement, aiming to integrate malaria prevention into everyday health services for broader protection.

In scientific advancements, MalariaWorld details...

Recent developments in malaria control highlight both challenges and advances, with a spotlight on vaccines amid stalled progress in reducing child deaths. The World Health Organization reported on March 19, 2026, that malaria remains the leading killer of children beyond their first month worldwide, causing 17% of under-five deaths in 2024, primarily in sub-Saharan Africa's endemic areas like Chad, the Democratic Republic of the Congo, Niger, and Nigeria. WHO Director-General Tedros Adhanom Ghebreyesus noted that while global under-five mortality has halved since 2000, reductions have slowed by over 60% since 2015, with conflicts exacerbating preventable fatalities.

Vaccine rollout continues to expand, offering a key defense...

Recent breakthroughs in malaria research highlight promising advances in drugs, vaccines, and detection tools, even as the disease remains a top killer of children worldwide. Early clinical trials of a new dual-action antimalarial drug candidate, MK-7602, show it is well tolerated in humans and targets enzymes in Plasmodium falciparum and Plasmodium vivax parasites, potentially curbing drug resistance, according to the Walter and Eliza Hall Institute (WEHI). This compound, developed over nearly a decade by WEHI and MSD researchers led by Professor Alan Cowman and Dr. David Olsen, blocks two essential parasite enzymes for a dual strategy backed by Wellcome Trust...

# Recent Developments in Malaria Research and Vaccination

Recent developments in malaria treatment and prevention have marked significant progress in the global fight against the disease. Just two days ago, on March 18, 2026, the Food and Drug Administration approved a major advancement in blood safety measures. The FDA licensed Grifols' Procleix Plasmodium assay for screening blood donors in the United States, becoming the second FDA-approved test for detecting malaria in blood supplies. This nucleic acid amplification test can identify RNA from five different Plasmodium species, including the most dangerous strains that affect humans. The approval also extends to screening organ...

A promising new malaria vaccine candidate has advanced in preclinical trials, offering hope for more effective protection against the deadly disease. MedicalXpress reports that an international team from Canada, the US, and the Netherlands developed the vaccine using the Canadian Light Source at the University of Saskatchewan. Published in Nature Communications on March 11, the study fused two potent proteins from the malaria parasite identified in blood samples of people with natural immunity, eliciting stronger immune responses than individual proteins alone.

Lead author Danton Ivanochko from Toronto's Hospital for Sick Children stated, "Our long-term goal is to eliminate malaria...

A breakthrough in malaria vaccine research has emerged from preclinical trials, offering hope against the deadly disease that claimed 610,000 lives worldwide in 2024, according to the World Health Organization. MedicalXpress reports that an international team from Canada, the US, and the Netherlands developed a novel vaccine by fusing the two most potent transmission proteins of the malaria parasite. Lead researcher Danton Ivanochko from Toronto's Hospital for Sick Children stated that this tandem antigen chimera elicited stronger immune responses and greater efficacy in animal models than previous candidates. Using the Canadian Light Source at the University of Saskatchewan, the team mapped antibody...

A new malaria vaccine candidate has shown strong promise in preclinical trials, eliciting potent immune responses by fusing key parasite proteins, according to MedicalXpress reporting on research published March 11 in Nature Communications. Lead author Danton Ivanochko from Toronto's Hospital for Sick Children explained that the innovation, developed using the Canadian Light Source at the University of Saskatchewan with international collaborators, targets transmission-blocking proteins identified in people with natural immunity. Structural mapping confirmed antibodies bind effectively at a molecular level, a crucial early validation that could fast-track it toward clinical trials in a few years if further tests succeed. Ivanochko emphasized...

Recent breakthroughs in malaria vaccine research highlight promising progress against Plasmodium vivax, the dominant strain in Asia and the Pacific, while funding challenges and rollout efforts intensify in Africa.

A study co-led by Australia's WEHI and Burnet Institute, published this week in Immunity, has unveiled how the human immune system combats P. vivax, offering a blueprint for the first effective vaccine targeting this elusive parasite. According to WEHI Laboratory Head Dr. Rhea Longley, global efforts have long prioritized P. falciparum, leaving critical gaps for P. vivax, which features a dormant liver stage causing relapses that hinder elimination. Burnet...

Recent breakthroughs in malaria vaccine research and rollout highlight growing momentum against the disease, particularly in Africa. On March 2, Gavi's VaccinesWork reported dramatic reductions in child hospitalizations and deaths in Nigeria's Kebbi State one year after introducing the R21/Matrix-M vaccine. Over 200,000 children received at least a first dose starting December 2024, with hospital records showing up to 50% fewer malaria cases among inpatients and outpatients. Health worker Maimunatu Abubakar at Nassarawa Maternal and Child Health Centre noted weekly admissions dropped from 12 to four children, with no malaria deaths since June 2025. At Takalau Primary Health Centre, monthly cases halved from 40 to 15-20...

Recent breakthroughs in malaria vaccine research and real-world impacts highlight growing momentum against the disease. A study published on March 3, 2026, in Immunity, co-led by Australia's WEHI and Burnet Institute, has mapped the human immune response to Plasmodium vivax, the dominant malaria strain in Asia and the Pacific, revealing a blueprint for the first effective vaccine against it. According to Burnet Institute researchers, protective immunity hinges not just on antibody presence but on their function in recruiting immune cells to target multiple parasite proteins, slashing malaria risk by over 75 percent when effective. This addresses a critical gap, as existing vaccines like...

Researchers from the Walter and Eliza Hall Institute (WEHI) and Burnet Institute have identified key immune targets for a Plasmodium vivax malaria vaccine, according to a study published in Immunity and reported by Technology Networks. The research, co-led by Dr. Rhea Longley and Professor Ivo Mueller, analyzed blood samples from children in Papua New Guinea, revealing that functional antibodies targeting multiple parasite proteins can reduce malaria risk by over 75 percent. Unlike Plasmodium falciparum, which has existing vaccines, P. vivax's dormant liver stage complicates elimination, and this work provides a blueprint for vaccine design by showing how antibodies recruit immune cells...

The World Health Organization has fully approved the rollout of the second malaria vaccine, R21/Matrix-M, for children under five in high-endemic areas, two years after recommending the first, RTS,S/AS01. According to a February 24, 2026, broadcast by Nigeria's NTA and Global Malaria Network, this builds on pilots in Kenya, Ghana, and Malawi that provided evidence for deployment starting in 2022.

Nigeria launched its R21 vaccine program in November 2024, targeting children under one year in high-burden states like Kebbi and Borno, supported by Gavi, UNICEF, and WHO. Integrated into routine immunization with a four-dose schedule, it aims to tackle...

Ehime University and Sumitomo Pharma announced on February 20, 2026, the launch of joint research on a novel multi-stage malaria vaccine targeting both liver and blood stages of Plasmodium falciparum infection. According to their press release, the vaccine combines PfCSP and the newly discovered PfRipr5 antigens with Sumitomo Pharma's TLR7 adjuvant DSP-0546E, aiming to prevent mosquito transmission and subsequent disease onset. The project, involving PATH, Statens Serum Institut, and the University of Copenhagen, received a grant from Japan's GHIT Fund to produce the vaccine and achieve non-clinical proof of concept over two years starting October 2025. This builds on prior collaborations, including...

Ehime University and Sumitomo Pharma announced on February 20, 2026, the launch of joint research on a novel multi-stage malaria vaccine, backed by a grant from Japan's Global Health Innovative Technology Fund, or GHIT Fund. The project, involving PATH in the USA, Statens Serum Institut in Denmark, and the University of Copenhagen, targets a vaccine combining PfCSP, a liver-stage antigen identified by SSI, and PfRipr5, a blood-stage antigen discovered through prior Ehime-Sumitomo collaboration, presented on nanoparticles with Sumitomo's TLR7 adjuvant DSP-0546E. Sumitomo Pharma's press release states this approach aims to block Plasmodium falciparum infection from mosquitoes and subsequent red blood cell...

Benin announced plans on February 18 to launch a National Agency to Combat Malaria and Mosquitoes, aiming to sharpen its fight against the disease that sickens 17% of adults and 39% of children under five annually, with a child mortality rate of 106 deaths per 100,000, according to the National Malaria Control Program. Ecofin Agency reports the agency will coordinate mosquito control, innovation, research, and awareness to cut incidence and economic burdens.

This builds on Benin's April 2024 rollout of the malaria vaccine in its immunization program, targeting 104,841 children aged 6 to 18 months in 16 health districts to shield kids and pregnant women.

Globally...

I appreciate your detailed request, but I need to clarify an important limitation with your query. You've asked me to focus on news and information from the past two days (February 15-17, 2026), however, the search results provided do not contain articles or announcements dated within that specific timeframe.

The most recent content in the search results includes a Gavi webinar announcement scheduled for February 25, 2026, and articles from early February 2026 discussing malaria vaccine implementation in African countries. The substantive malaria vaccine news in these results dates from late 2025, when pricing agreements were announced.

To provide you with...

Tanzanian President Samia Suluhu Hassan urged stronger domestic financing and sustained political commitment to combat malaria across Africa, speaking on Saturday at a high-level media meeting on the sidelines of the 39th African Union Summit in Addis Ababa, according to Xinhua. She emphasized African ownership, accountability, and long-term investment to eradicate the disease, which she described as a key health, development, and economic priority. Tanzania, host of the African Leaders' Alliance for Malaria Action, has integrated interventions like insecticide-treated nets, malaria vaccines, and improved monitoring into its primary healthcare and Universal Health Coverage programs, with investments in research at the...

A landmark multi-country clinical trial has revealed more efficient treatments for Plasmodium vivax malaria, according to MedicalXpress reporting on February 12. The EFFORT Trial, led by Menzies School of Health Research and collaborators in Ethiopia, Pakistan, Indonesia, and Cambodia, confirmed the safety and effectiveness of high-dose primaquine over seven days and single-dose tafenoquine in G6PD-normal patients. Published in The Lancet Infectious Diseases, the study showed both regimens greatly reduced P. vivax recurrence compared to the standard 14-day low-dose primaquine course. Tafenoquine also performed well alongside artesunate-pyronaridine, paving the way for broader use with artemisinin-based therapies and influencing WHO guidelines.
<...

In Malawi, malaria continues to exert a heavy toll on the health system, with the Public Health Institute of Malawi reporting 51,408 cases and 8 deaths in Week 4 of 2026, amid peak transmission season. This slight dip in cases from prior weeks still underscores urgent needs for rapid diagnostic tests, antimalarial drugs, and long-lasting insecticidal nets, as health facilities prioritize severe cases to curb rising mortality.

Recent studies affirm the growing impact of the RTS,S/AS01E malaria vaccine, first rolled out in Ghana, Kenya, and Malawi. An interim analysis of the EPI-MAL-003 study, published in The Lancet and highlighted...

New malaria vaccines are dramatically reducing child deaths in Ghana, marking a breakthrough against a disease that claims nearly half a million young lives annually in Africa. According to The Japan Times on February 2, the vaccines from British drugmaker GSK and Oxford University with the Serum Institute of India have helped slash mortality rates, building on Ghana's progress with insecticide-treated bed nets and preventive drugs. Dr. Selorm Kutsoati, head of Ghana's immunization program, credits the shots with closing the remaining gap toward eliminating child malaria deaths.

The World Health Organization reinforced this momentum in Director-General Tedros Adhanom Ghebreyesus's...

New malaria vaccines are driving down child deaths in Ghana and expanding across Africa, but funding cuts threaten further progress, according to recent reports from Gavi and the Japan Times. In Ghana, shots developed by British drugmaker GSK and by Oxford University with the Serum Institute of India have helped slash malaria mortality, building on bed nets and preventive drugs to approach the goal of zero child deaths from the disease, which kills nearly half a million young Africans yearly. Dr. Selorm Kutsoati, head of Ghana's immunization program, credits the vaccines with closing remaining gaps, as detailed in the Japan...

The World Health Organization announced on February 2, 2026, that it has supported seven new countries in introducing malaria vaccines, raising the total to 24 nations, as stated by Director-General Tedros Adhanom Ghebreyesus in opening remarks at the 158th Executive Board session. Gavi, the Vaccine Alliance, echoed this progress on the same day, reporting that malaria vaccines have reached 24 countries after exceeding targets for HPV vaccinations amid a challenging year.

Recent research underscores ongoing advancements and hurdles for malaria vaccines. A January 2026 report from Malaria Partners International highlights a Nature Medicine study published January 6, showing the R21/Matrix-M vaccine provided high...

# Malaria Vaccine Shows Significant Real-World Impact in African Children

A landmark study published in The Lancet Global Health has demonstrated that the RTS,S/AS01E malaria vaccine, developed by GSK and recommended by the World Health Organization in 2021, substantially reduces malaria cases and hospitalizations among vaccinated children in sub-Saharan Africa. The interim phase 4 analysis represents a major milestone in the global fight against one of the world's deadliest infectious diseases.

According to the research findings, children who received the four-dose vaccine series between ages five months and two years experienced markedly lower rates of both...

# Malaria Vaccine Shows Significant Real-World Impact in Africa

A major breakthrough in malaria prevention has emerged from sub-Saharan Africa, where the RTS,S/AS01E vaccine continues to demonstrate remarkable effectiveness in protecting children from the disease. According to research published in The Lancet Global Health, vaccinated children experienced substantially fewer clinical malaria cases and hospitalizations for severe malaria compared with unvaccinated peers, even in regions where insecticide-treated bed nets and other preventive measures are widely available.

The vaccine, developed by GSK and first recommended by the World Health Organization in 2021, targets Plasmodium falciparum, the deadliest...

# Malaria Vaccine Expansion Marks Major Progress in Global Disease Control

Recent developments in malaria vaccination demonstrate significant strides in protecting children across Africa, with expanded rollouts and real-world effectiveness data reshaping disease prevention efforts.

According to The Lancet Global Health, an interim phase 4 analysis shows that children receiving the RTS,S/AS01E malaria vaccine experienced markedly lower rates of malaria and severe malaria compared with unvaccinated peers. The vaccine, developed by GSK and first recommended by the World Health Organization in 2021, targets Plasmodium falciparum, the deadliest malaria parasite. Administered as a four-dose series between five...

In rural Lilongwe, Malawi, mothers like Audeta Phiri are crossing rivers and defying myths to vaccinate their children against malaria, according to UNICEF Malawi's report on January 16. At Chileka Health Centre, health workers vaccinated over 3,000 children in 2025, surpassing targets through community training and engagement with volunteers and traditional leaders, though religious fears and misconceptions persist.

On January 19, the Global Health EDCTP3 Joint Undertaking announced 36 new projects funded with 215 million euros to tackle health priorities in sub-Saharan Africa, including three under the malaria therapeutics call for new antimalarial candidates. Grant agreements are set for early 2026, with details forthcoming after...

# Malaria Vaccine Progress: New Discoveries and Community Successes

Recent developments in malaria prevention show encouraging progress on multiple fronts, from grassroots vaccination campaigns to cutting-edge research into next-generation treatments.

In Malawi, community-driven vaccination efforts are overcoming longstanding vaccine hesitancy, according to reporting from UNICEF Malawi on January 16, 2026. Health facilities across 11 malaria-implementation districts have significantly increased vaccine uptake through targeted community engagement. At Chileka Health Centre west of Lilongwe, vaccinators administered 3,061 doses in 2025 alone, surpassing initial targets. The success stems from training traditional leaders, community volunteers, and early childhood development caregivers to counter persistent myths claiming the...

A new World Health Organization report reveals that global efforts averted one million malaria deaths in 2024, even as the disease saw 282 million cases worldwide, a three percent rise from the prior year, according to Infectious Disease Special Edition on January 13. The report highlights progress from tools like vaccines but warns of growing drug resistance threatening future gains.

In Kenya's remote Wasini Island, where malaria remains endemic alongside diseases like typhoid and diarrhea, health workers at the local dispensary are pushing routine vaccinations to protect children, Gavi, The Vaccine Alliance reported on January 15. Nurse Hassan Arafat Mruche noted scarce...

Replicate Bioscience announced on January 8, 2026, that it received approximately $7 million in grants from the Gates Foundation to develop novel self-replicating RNA (srRNA) vaccines for malaria and HIV, according to a PR Newswire release. A $3.5 million grant targets a low-dose, multigenic RNA-based malaria vaccine platform aimed at improving access in low- and middle-income countries, where the disease kills over 600,000 people annually, mostly young children and pregnant women. Replicate's Chief Executive Officer Nathaniel Wang stated the srRNA technology promises better durability, dose sparing, and safety compared to existing vaccines, leveraging clinical data from their rabies vaccine RBI-4000.

The World Health...

Global efforts to curb malaria are entering a new phase, with recent developments in vaccine research and funding underscoring both the promise and the remaining gaps in protection against the disease.

Replicate Bioscience announced this week that it has been awarded approximately 7 million dollars in grants from the Bill & Melinda Gates Foundation to develop new self‑replicating RNA vaccines for HIV and malaria. According to the company, about 3.5 million dollars will support a low‑dose, multigenic RNA-based malaria vaccine platform designed to expand access to effective prevention tools in low- and middle-income countries. Replicate Bioscience says its self‑replic...